Interaction Checker

Interacciones de Riluzol

Riluzol (Rilutek, Tiglutik, Exservan) tiene 36 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 33; leves: 3; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (33)

  • Cannabidiol (con receta)anticonvulsivoModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • EstradiolestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Estrógenos conjugados y bazedoxifenoestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Estrógenos esterificados y metiltestosteronaestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Etonogestrel y etinilestradiolestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • FluvoxaminaISRSModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • FulvestrantestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • LevonorgestrelprogestágenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • MedroxiprogesteronaprogestágenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • MegestrolprogestágenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • MexiletinaantiarrítmicoModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Norelgestromina y etinilestradiolestrógenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • NoretisteronaprogestágenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • ProgesteronaprogestágenoModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Viloxazinainhibidor de la recaptación de noradrenalinaModerada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

  • Zileutóninhibidor de CYP1A2Moderada

    Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (etiqueta de Riluzol, Interacciones medicamentosas)

Menciones leves (3)

  • Alopurinolinhibidor de la xantina oxidasaLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (etiqueta de Riluzol, Interacciones medicamentosas)

  • MetildopaantihipertensivoLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (etiqueta de Riluzol, Interacciones medicamentosas)

  • SulfasalazinasulfonamidaLeve

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (etiqueta de Riluzol, Interacciones medicamentosas)

Compruebe Riluzol frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.